Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker
From MaRDI portal
Publication:3465715
Recommendations
- Reader reaction on `Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker'
- Data-adaptive efficient estimation strategies for biomarker studies embedded in randomized trials
- Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpoint
- Adaptive enrichment designs with a continuous biomarker
- The use of covariates and random effects in evaluating predictive biomarkers under a potential outcome framework
Cites work
Cited in
(4)- Estimating the superiority of a drug to a placebo when all and only those patients at risk are treated with the drug.
- Addressing small sample size bias in multiple-biomarker trials: inclusion of biomarker-negative patients and firth correction
- Reader reaction on `Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker'
- Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials
This page was built for publication: Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3465715)